Oxcarbazepine (Epilepsy)

Limb defects

R analysis
id Study   Lib. in paper Exposition period    Study type 
 Control type 
 
Tags OR 95%CI x1/n1 x0/n0 no cases no exposed ROB Ref.
S12828
R48303		 Thomas (Oxcarbazepine) (Controls exposed to Lamotrigine, sick), 2021 Skeletal malformations 1st trimester prospective cohort exposed to other treatment, sick excluded Adjustment: No 2.14 [0.09;53.55] C
excluded (control group) 		1/71   0/50 1 71
ref
S12830
R48315		 Thomas (Oxcarbazepine) (Controls unexposed, sick), 2021 Skeletal malformations 1st trimester prospective cohort unexposed, sick Adjustment: No 2.41 [0.22;27.00] C 1/71   2/340 3 71
ref
S6071
R15804		 Morrow (Oxcarbazepine) (Controls exposed to Lamotrigine, sick), 2006 Skeletal abnormalities 1st trimester prospective cohort exposed to other treatment, sick Adjustment: No 19.83 [0.86;455.05] C 0/7   2/647 2 7
ref
S6096
R35921		 Artama (Oxcarbazepine), 2005 Certain musculoskeletal deformities and Other anomalies of limbs 1st trimester retrospective cohort (registry) unexposed, sick Adjustment: No 0.63 [0.04;11.12] C 0/99   7/939 7 99
ref
Total 3 studies 2.81 [0.46;17.19] 12 177
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives

Forest plot

StudyTE95% CIn casesn exposedweightROBABCDEF Thomas (Oxcarbazepine) (Controls unexposed, sick), 2021Thomas, 2021 1 2.41[0.22; 27.00]37141%ROB confusion: seriousROB selection: moderateROB classification: moderateROB missing: unclearROB mesure: moderateROB reporting: moderate Morrow (Oxcarbazepine) (Controls exposed to Lamotrigine, sick), 2006Morrow, 2006 2 19.83[0.86; 455.05]2727%ROB confusion: NAROB selection: NAROB classification: NAROB missing: NAROB mesure: NAROB reporting: NA Artama (Oxcarbazepine), 2005Artama, 2005 3 0.63[0.04; 11.12]79932%ROB confusion: NAROB selection: NAROB classification: NAROB missing: NAROB mesure: NAROB reporting: NA Total (3 studies) I2 = 22% 2.81[0.46; 17.19]121770.250.01.0ROB: A: confusion, B: selection, C: classification, D: missing, E: measurement, F: reportinglow,moderate,serious,critical,unclear,

1: Oxcarbazepine) (Controls unexposed, sick; 2: Oxcarbazepine) (Controls exposed to Lamotrigine, sick; 3: Oxcarbazepine;

Sensitivity analysis

SubsetTE95% CIn casesn exposedkI2 Type of studies cohort studiescohort studies 2.81[0.46; 17.19]1217722%NAThomas (Oxcarbazepine) (Controls unexposed, sick), 2021 Morrow (Oxcarbazepine) (Controls exposed to Lamotrigine, sick), 2006 Artama (Oxcarbazepine), 2005 3 case control studiescase control studies 0 Type of controls unexposed, sickunexposed, sick 1.38[0.22; 8.78]101700%NAThomas (Oxcarbazepine) (Controls unexposed, sick), 2021 Artama (Oxcarbazepine), 2005 2 exposed to other treatment, sickexposed to other treatment, sick 19.83[0.86; 455.05]27 -NAMorrow (Oxcarbazepine) (Controls exposed to Lamotrigine, sick), 2006 1 Tags Adjustment   - No  - No 2.81[0.46; 17.19]1217722%NAThomas (Oxcarbazepine) (Controls unexposed, sick), 2021 Morrow (Oxcarbazepine) (Controls exposed to Lamotrigine, sick), 2006 Artama (Oxcarbazepine), 2005 3 All studiesAll studies 2.81[0.46; 17.19]1217722%NAThomas (Oxcarbazepine) (Controls unexposed, sick), 2021 Morrow (Oxcarbazepine) (Controls exposed to Lamotrigine, sick), 2006 Artama (Oxcarbazepine), 2005 30.250.01.0

Publication bias and p-hacking diagnosis

funnel plot

Funnel plot not drawn. Less than 3 points.

Asymetry test p-value = NaN (by Egger's regression)

not enought points

p values plot

Funnel plot not drawn. Less than 3 points.

Sub-groups analysis using all included studies

excluded 12828

Sub-groupsTE95% CIn casesn exposedkI2ROB type of controls unexposed, sick controlsunexposed, sick controls 1.38[0.22; 8.78]101700%NAThomas (Oxcarbazepine) (Controls unexposed, sick), 2021 Artama (Oxcarbazepine), 2005 2 exposed to other treatment, sick controlsexposed to other treatment, sick controls 6.71[0.71; 63.45]3780%NAThomas (Oxcarbazepine) (Controls exposed to Lamotrigine, sick), 2021 Morrow (Oxcarbazepine) (Controls exposed to Lamotrigine, sick), 2006 20.510.01.0